0102030405
High-Purity Pramiracetam CAS 68497-62-1 - Neuroprotection Supplier & Factory in China
Brief Introduction
Pramiracetam (development codes: CI-879, CNS-1879) is a second-generation nootropic derived from piracetam, developed by Warner-Lambert Company. As an improved member of the racetam family, Pramiracetam features a diisopropylaminoethyl side chain that significantly enhances its lipophilicity, resulting in greater potency than Piracetam. Pramiracetam is primarily used in research on cognitive dysfunction associated with traumatic brain injury, cerebrovascular disorders, and aging.
Key Scientific Value & Findings
🧠 Enhanced Cognitive Improvement
Pramiracetam significantly ameliorates cognitive deficits associated with traumatic brain injury. In animal models, Pramiracetam plays an important role in spatial learning and memory and is considered a memory-enhancing agent stronger than piracetam.
⚗️ Unique Enzyme Inhibition Mechanism
Pramiracetam is a specific inhibitor of prolyl endopeptidase. Prolyl endopeptidase is involved in neuropeptide metabolism, and its inhibition may be related to the cognitive-enhancing effects of Pramiracetam, offering a unique perspective for understanding its mechanism of action.
🔗 Receptor Binding Profile
In vitro studies demonstrate that Pramiracetam exhibits no affinity for dopaminergic, GABAergic, serotonergic, adrenergic, muscarinic, adenosine (IC50 >10 μM), or benzodiazepine (IC50 >1 μM) receptor binding sites. This suggests its cognitive-enhancing effects are not achieved through direct activation of classical neurotransmitter receptors.
⚡ Proposed Mechanism of Action
Review studies indicate that the action of racetams (including Pramiracetam) may be due to potentiation of already present neurotransmission, with evidence pointing to modulation of ion flux—such as potentiated calcium influx through non-L-type voltage-dependent calcium channels, potentiated sodium influx through AMPA receptor-gated channels or voltage-dependent channels, or decreased potassium efflux. Pramiracetam is also thought to improve cognitive function by enhancing GluA4 subunit-mediated neurotransmission.
🔄 Cholinergic System Modulation
Research shows that Pramiracetam reverses amnesia induced by scopolamine, electroconvulsive shock, and hypoxia. It also increases the turnover of various neurotransmitters and exhibits other biochemical effects, including the aforementioned inhibition of prolyl endopeptidase.
Our Supply & Service Advantages
❓ Frequently Asked Questions (FAQ)
What is Pramiracetam and how does it differ from Piracetam?
Pramiracetam is a second-generation racetam nootropic developed from piracetam. It features a diisopropylaminoethyl side chain that significantly increases its lipophilicity, making it considerably more potent than the original piracetam compound.
What are the primary research applications of Pramiracetam?
Pramiracetam is primarily used in research focusing on cognitive dysfunction associated with traumatic brain injury, cerebrovascular disorders, and age-related cognitive decline.
How does Pramiracetam work at the neurochemical level?
Pramiracetam is thought to work by potentiating existing neurotransmission through modulation of ion flux—including calcium and sodium influx and potassium efflux—as well as enhancing GluA4 subunit-mediated neurotransmission and inhibiting the enzyme prolyl endopeptidase.
Does Pramiracetam bind to common neurotransmitter receptors?
No. In vitro studies show that Pramiracetam exhibits no significant affinity for dopaminergic, GABAergic, serotonergic, adrenergic, muscarinic, adenosine, or benzodiazepine receptor binding sites, distinguishing its mechanism from many other cognitive-affecting compounds.
What role does prolyl endopeptidase inhibition play in Pramiracetam's effects?
Pramiracetam acts as a specific inhibitor of prolyl endopeptidase, an enzyme involved in neuropeptide metabolism. This inhibition is considered one of the unique mechanisms through which Pramiracetam may exert its cognitive-enhancing effects.
Can Pramiracetam reverse amnesia in research models?
Yes. Research demonstrates that Pramiracetam can reverse amnesia induced by scopolamine, electroconvulsive shock, and hypoxia in experimental models, and it has shown notable effects on spatial learning and memory enhancement compared to piracetam.